In a significant breakthrough in Alzheimer’s research, recent findings have revealed promising results for a drug known as Lecanemab, marketed under the name Leqembi. This medication targets the beta-amyloid protein, which is associated with the formation of plaques in the brain believed to be a key factor in the progression of Alzheimer’s disease. A large clinical study involving nearly 1,800 patients showed that Lecanemab reduced the rate of cognitive decline by up to 27% over 18 months compared to those who received a placebo. The treatment also helped patients maintain their independence for approximately 10 months longer.
Moreover, results from real-world trials outside the strict clinical framework indicated that the drug is relatively safe. Only a small percentage of patients in the very early stages of the disease experienced mild side effects. Lecanemab has been officially approved in the United States, making it the first medication to modify the course of Alzheimer’s based on a clear and targeted mechanism.
In parallel, another drug called Donanemab, recently marketed as Kisunla, has also demonstrated notable effectiveness. It slowed cognitive decline by up to 35% over 18 months, making it a strong competitor among immune-based Alzheimer’s therapies. Significant improvements have been made to Donanemab to reduce its associated risks most notably, a reduction in the incidence of brain swelling (ARIA-E) from 24% to 14%, without compromising the drug's efficacy.
Looking to the future, promising studies are underway to evaluate anti-amyloid drugs as preventive treatments. One such study suggests that administering these medications to people with a high genetic risk—even before any symptoms appear—could lower the chance of developing Alzheimer’s by nearly 50% over eight years. A new drug currently in testing, called Remternetug, is a next-generation version of Donanemab designed for injection instead of intravenous infusion. It is being evaluated for its ability to prevent plaque formation in the brain at pre-symptomatic stages.
These developments represent a true beacon of hope not just for slowing the progression of Alzheimer’s, but potentially for preventing it altogether in high-risk populations.